Clinical trial
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's…
NCT00060294 · Jonsson Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00060294 |
|---|---|
| Title | Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia |
| Official title | Phase I Study of Zevalin (90Y-Ibritumomab Tiuxetan) in Waldenstrom's Macroglobulinemia (Lymphoplasmacytic Lymphoma) |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Radiation |
| Interventions | rituximab, yttrium Y 90 ibritumomab tiuxetan |
| Start date | Apr 1, 2003 |
| Primary completion | Jun 1, 2004 |
| First posted | May 7, 2003 |
| Last update posted | Jan 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: